June 8, 2017
Cambridge, Ma

New Grant Funding from Save Our Sons and Join Our Boys

Solid Biosciences is pleased to announce an additional AUD 500,000 research grant from our Australia-based partner Save Our Sons and an initial EUR 100,000 research grant from Ireland-based Join Our Boys.

“The funds we receive from DMD charities support Solid’s 360-degree approach to tackling DMD, enabling us to quickly and efficiently validate new scientific approaches and move forward only what we believe has the greatest potential for success. Funding also allows us to stay ahead of the emerging DMD scientific landscape, and remain focused on addressing the entire spectrum of the disease,” said Annie Ganot, Head of Patient Advocacy for Solid.

Save Our Sons Duchenne Foundation has allocated AUD 500,000 to support studies aimed at understanding and circumventing antibody responses to adeno-associated virus (AAV), with the goal of enabling re-administration of gene therapies. These studies are being conducted in collaboration with Barry Byrne, M.D., Ph.D., Director of the University of Florida Powell Gene Therapy Center, based on exciting preliminary data generated by his group. This substantial grant marks an additional milestone in Solid’s ongoing partnership with the Australian-based charity.

Join Our Boys has allocated EUR 100,000 to support exploratory methods to accelerate understanding of gene therapy vector activity. These studies will support Solid’s efforts to develop current and future gene therapy approaches.

Related news


The Solid Biosciences team was honored to join the Duchenne muscular dystrophy community in recognizing World Duchenne Awareness Day.

Only together can we end this devastating disease.


We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.


Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial


Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.


Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day


Today we are excited to announce the initiation of our first clinical trial for SGT-001.


We are getting ready to initiate a clinical study for our gene transfer candidate, SGT-001, later this year.


The Duchenne Research Fund (DRF) provided Solid with a research grant of $600,000 to support its LTBP4 program to combat fibrosis and to support novel biomarker work in Duchenne muscular dystrophy (DMD).


It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.


Solid was proud to sponsor the 8th Annual Gals For Cal team at the recent Max Performance Title 9 Triathlon at Hopkinton State Park in Massachusetts.


More information about Solid?

Please subscribe to receive our latest news